Table 4.
Examination characteristics in MDZ group and DEX group before propensity score matching.
| MDZ group | DEX group | |
|---|---|---|
| N | 166 | 111 |
| Insertion route | ||
| Peroral | 68 (41.0%) | 56 (50.5%) |
| Transanal | 98 (59.0%) | 55 (49.5%) |
| Endoscopes | ||
| Therapeutic (EN-450T, 580T) | 111 (66.9%) | 87 (78.4%) |
| Diagnostic (EN-450P, 580XP) | 55 (33.1%) | 24 (21.6%) |
| Duration of insertion (min) | 42.6 ± 21.8 | 45.5 ± 20.0 |
| Total duration of examination (min) | 63.2 ± 23.3 | 68.4 ± 25.6 |
| Polypectomy | 6 (3.6%) | 8 (7.2%) |
| Hemostasis | 15 (9.0%) | 3 (2.7%) |
| Endoscopic balloon dilation | 10 (6.0%) | 3 (2.7%) |
| Endoscopic ultrasound | 3 (1.8%) | 7 (6.3%) |
| DEX (mg/kg) | 1.64 ± 0.4 | |
| MDZ (mg) | 15.6 ± 5.8 | 3.5 ± 2.4 |
| Pentazocine (mg) | 16.4 ± 7.3 | 26.5 ± 15.8 |
| Body motion | 46 (27.7%) | 13 (11.7%) |
| Hypotension | 7 (1.2%) | 13 (11.7%) |
| Respiratory depression | 128 (77.1%) | 55 (49.5%) |
| Bradycardia | 6 (3.6%) | 2 (1.8%) |
MDZ: midazolam; DEX: dexmedetomidine.